A Single Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs IM 156 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors ImmunoMet Therapeutics
- 29 Sep 2017 Status changed from not yet recruiting to recruiting.
- 01 Sep 2017 Planned initiation date changed from 1 Jun 2017 to 1 Sep 2017.
- 01 Sep 2017 Status changed from planning to not yet recruiting.